Seaport Therapeutics, Inc. (SPTX)
Data as of , from SEC Form 4 filings.
See up to 3 months of SPTX. The 7-day demo opens the 1M and 3M ranges and puts SPTX on your watchlist.
Start 7-day demoLatest SPTX insider trades
Robert J. HombachOpen-market purchase$236K- ARCH Venture Partners XII, LLCOpen-market purchase$19.80M
- PureTech Health plcOther
About Seaport Therapeutics, Inc. (SPTX)
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
- BOSTON, MA
- 2026
- XNAS
SPTX Form 4 activity by transaction type, last 90 days
No Form 4 activity for SPTX in the last 90 days.
SPTX insider transactions (Form 4)
4115 Form 4 filings on record, the earliest from May 4, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Robert J. Hombach | Open-market purchase | Common Stock | 13,000 | $18.14 footnote F1 | $236K | |
| ||||||
| PureTech Health plc | Other | Common Stock | 12,736,014 | - footnote F1 | - | |
| PureTech Health plc | Other | Common Stock | 2,681,265 | - footnote F1 | - | |
| PureTech Health plc | Other | Common Stock | 965,255 | - footnote F1 | - | |
| PureTech Health plc | Other | Series A-1 Preferred Stock | 40,000,000 | $0.00 | - | |
| PureTech Health plc | Other | Series A-2 Preferred Stock | 8,421,052 | $0.00 | - | |
| PureTech Health plc | Other | Series B Preferred Stock | 3,031,578 | $0.00 | - | |
| ||||||
 Daphne Zohar - Officer | Grant or award | Stock Option (Right to Buy) | 271,813 | $0.00 | - | |
| Daphne Zohar - Officer | Grant or award | Stock Option (Right to Buy) | 1,486,786 | $0.00 | - | |
| James Healy | Other | Common Stock | 1,927,159 | - footnote F1 | - | |
| James Healy | Other | Common Stock | 804,379 | - footnote F1 | - | |
| James Healy | Other | Series A-2 Preferred Stock | 6,052,631 | $0.00 | - | |
| James Healy | Other | Series B Preferred Stock | 2,526,315 | $0.00 | - | |
| ||||||
 Lauren White - Officer | Other | Common Stock | 6,702 | - footnote F1 | - | |
| Lauren White - Officer | Grant or award | Stock Option (Right to Buy) | 63,680 | $0.00 | - | |
| Lauren White - Officer | Other | Series B Preferred Stock | 21,052 | $0.00 | - | |
| ||||||
 David E. Wheadon | Grant or award | Stock Option (Right to Buy) | 12,258 | $0.00 | - | |
 Sandra E. Peterson | Grant or award | Stock Option (Right to Buy) | 12,258 | $0.00 | - | |
 Lana Gladstein - Officer | Other | Common Stock | 33,515 | - footnote F1 | - | |
| Lana Gladstein - Officer | Grant or award | Stock Option (Right to Buy) | 63,680 | $0.00 | - | |
| Lana Gladstein - Officer | Other | Series B Preferred Stock | 105,263 | $0.00 | - | |
| ||||||
 Michael Cunyuan Chen - Officer | Other | Common Stock | 3,351 | - footnote F1 | - | |
| Michael Cunyuan Chen - Officer | Grant or award | Stock Option (Right to Buy) | 63,680 | $0.00 | - | |
| Michael Cunyuan Chen - Officer | Other | Series B Preferred Stock | 10,526 | $0.00 | - | |
| ||||||
| Denice Torres | Other | Common Stock | 13,406 | - footnote F1 | - | |
| Denice Torres | Grant or award | Stock Option (Right to Buy) | 12,258 | $0.00 | - | |
| Denice Torres | Other | Series B Preferred Stock | 42,105 | $0.00 | - | |
| ||||||
 Steven M. Paul | Grant or award | Stock Option (Right to Buy) | 991,192 | $0.00 | - | |
| Steven M. Paul | Other | Common Stock | 67,031 | - footnote F1 | - | |
| Steven M. Paul | Grant or award | Stock Option (Right to Buy) | 12,258 | $0.00 | - | |
| Steven M. Paul | Other | Series B Preferred Stock | 210,526 | $0.00 | - | |
| ||||||
| ARCH Venture Partners XII, LLC | Other | Common Stock | 2,513,686 | - footnote F1 | - | |
| ARCH Venture Partners XII, LLC | Other | Common Stock | 2,681,265 | - footnote F1 | - | |
| ARCH Venture Partners XII, LLC | Open-market purchase | Common Stock | 1,100,000 | $18.00 | $19.80M | |
| ARCH Venture Partners XII, LLC | Other | Series A-2 Preferred Stock | 2,513,686 | $0.00 | - | |
| ARCH Venture Partners XII, LLC | Other | Series B Preferred Stock | 2,681,265 | $0.00 | - | |
| ||||||
| Robert J. Hombach | Grant or award | Stock Option (Right to Buy) | 12,258 | $0.00 | - | |
 Antony Loebel - Officer | Other | Common Stock | 20,109 | - footnote F1 | - | |
| Antony Loebel - Officer | Grant or award | Stock Option (Right to Buy) | 63,680 | $0.00 | - | |
| Antony Loebel - Officer | Other | Series B Preferred Stock | 63,157 | $0.00 | - | |
| ||||||
| Sharon Mates | Grant or award | Stock Option (Right to Buy) | 49,033 | $0.00 | - | |
Item 2.02, 9.01
Item 2.02, 9.01
Item 5.03, 9.01
SPTX insider trading FAQ
What is the latest insider trade for SPTX?
Seaport Therapeutics, Inc. (SPTX) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-06-24. The full record for SPTX runs to 15 Form 4 filings, the earliest from 2026-05-04. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying SPTX stock?
No insider purchases of SPTX were filed in the last 90 days. 2 purchases are on record for this company.
How many insiders are selling SPTX stock?
No insider sales of SPTX were filed in the last 90 days.
Where can I see SPTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects SPTX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Robert J. Hombach view on EDGAR
- - PureTech Health plc view on EDGAR
- - Daphne Zohar view on EDGAR
- - James Healy view on EDGAR
- - Lauren White view on EDGAR
- - David E. Wheadon view on EDGAR
- - Sandra E. Peterson view on EDGAR
- - Lana Gladstein view on EDGAR
- - Michael Cunyuan Chen view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where SPTX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow SPTX with a 7-day demo
- SPTX on your watchlist
- Every SPTX Form 4 filing on record
- Up to 3 months of SPTX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
